In the world of breast cancer care, big changes are happening — and they’re offering patients more hope and gentler treatment options than ever before.
“Early detection is still the key,” said Dr. Neil B. Friedman, director of the Hoffberger Breast Center at Mercy Medical Center in Baltimore. “The earlier you detect it, the better patients do — and the less aggressive you can be with treatment.”
One of the newer tools aiding early detection is contrast-enhanced mammography. This imaging technique involves using a contrast agent, similar to what’s used in certain CT scans, during a mammogram.
The result is a clearer, more detailed image that can help detect tumors that might otherwise be missed.
“It’s especially useful for women with dense breast tissue, or those with a high genetic or family risk,” Friedman explained.
While not yet the standard of care, it’s increasingly being used in higher-risk cases to find cancers sooner and more accurately.
When it comes to surgery, most patients today are eligible for breast-conserving procedures like lumpectomies rather than full mastectomies.
“About 60% to 70% of patients can be treated with a lumpectomy followed by radiation,” Friedman said, noting that the choice also depends on personal preferences and where the patient lives.
Radiation therapy itself has changed dramatically.
“It used to be six and a half weeks of daily treatment,” Friedman said. “Now, most patients only need three and a half weeks and some can finish in just five days.” This shift not only shortens treatment time but also lowers the burden on patients’ daily lives.
Another major change is how doctors decide whether chemotherapy is necessary. Rather than relying solely on tumor size or lymph node involvement, physicians now use genomic tools like Oncotype DX, which analyzes the biological makeup of the tumor.
“It helps us predict who really needs chemo and who doesn’t,” Friedman said. “We’re moving toward giving less aggressive chemo when possible.”
For patients with advanced or metastatic disease, new treatments are showing real promise.
Among them are antibody-drug conjugates, medications that combine chemotherapy with targeted antibodies to deliver cancer-killing drugs more directly to tumor cells, often with fewer side effects.
Clinical trials for breast cancer vaccines are also underway across the country. These experimental therapies aim to train the immune system to recognize and attack cancer cells.
“There’s a lot in the pipeline,” Friedman said. “Every year, more options are becoming available.”
All these advances are changing the outlook for people living with metastatic breast cancer.
“Ten years ago, most people with advanced disease died within two to five years,” Friedman said. “Now, some are living 10 years or more — and with good quality of life.”
Thanks to these innovations, breast cancer mortality has dropped by roughly 35% to 40% in the last two decades, even though the number of annual diagnoses continues to rise.
For patients today, the message is clear: Breast cancer treatment is becoming more personalized, less invasive and more hopeful than ever before.
